GlassScriptPhysician profile
John R Jones
NPI 1265403570
$12,845.30
in general payments reported to CMS, 2019-2025
47 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,450 · 2020: $1,344 · 2021: $3,144 · 2022: $1,211 · 2023: $1,278 · 2024: $1,890 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,674 · Education: $21.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,673.98 |
| Education | $21.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,086.80 | 2019-2025 | Yeztugo, Biktarvy |
| Viiv Healthcare Company | $1,782.80 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Novo Nordisk INC | $898.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Biotech, INC. | $725.00 | 2019-2023 | Symtuza |
| Astrazeneca Pharmaceuticals LP | $661.58 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $593.67 | 2019-2022 | |
| Abbvie INC. | $582.58 | 2019-2024 | |
| Emd Serono, INC. | $543.16 | 2019-2024 | Serostim, Serostim |
| Amgen INC. | $503.19 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $368.56 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.39 | 2019-2024 | Jardiance |
| Antares Pharma, INC. | $294.96 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $294.72 | 2019-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $274.19 | 2019-2022 | |
| Theratechnologies INC. | $271.60 | 2019-2025 | Trogarzo, Egrifta |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.